Dendritic Cell Vaccines in Ovarian Cancer: Have We Reached Their Potential?
DOI:
https://doi.org/10.65539/f020tm68Keywords:
ovarian cancer, dendritic cell vaccines, immunotherapy, cancer vaccines, neoantigensAbstract
Ovarian cancer is the most lethal gynecological malignancy, largely driven by high rates of relapse and chemoresistance. Ovarian cancer is thought to be immunogenic, making it amenable to immunotherapy. However, immunotherapies such as PD-L1 inhibitors and T cell transfers have produced modest, if any, survival benefit. One particular immunotherapy of interest is the dendritic cell vaccine, which delivers mature dendritic cells loaded with tumor antigens with the goal of mounting a T cell response against tumor cells. This review will focus on the role that dendritic cells play in the ovarian tumor microenvironment, general approaches to engineering dendritic cell vaccines and assessing their efficacy alone and in combination with other immunotherapies and systemic chemotherapies. Finally, we will discuss important areas of ongoing research in the field, including the development of personalized neoantigen-targeting DC vaccines.
Downloads
References
Siegel, R.L., Miller, K.D., Jemal, A. (2020). Cancer statistics. CA: A Cancer Journal for Clinicians, 70(1), 7-30. doi:10.3322/CAAC.21590
Gadducci, A., Cosio, S., Conte, P.F., Genazzani, A.R. (2005). Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Critical reviews in oncology/hematology, 55(2), 153-166. doi:10.1016/J.CRITREVONC.2005.03.003
Stuart, G.C.E. (2003). First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecologic oncology, 90(3 Pt 2), S8. doi:10.1016/S0090-8258(03)00472-4
Vonderheide, R.H., Hahn, W.C., Schultze, J.L., Nadler, L.M. (1999). The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10(6), 673-679. doi: 10.1016/s1074-7613(00)80066-7
Sato, E., Olson, S.H., Ahn, J., et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 102(51), 18538-43. doi: 10.1073/pnas.0509182102
Kandalaft, L.E., Odunsi, K., Coukos, G. (2019). Immunotherapy in ovarian cancer: Are we there yet? Journal of Clinical Oncology, 37(27), 2460-2471. doi:10.1200/JCO.19.00508
Varga, A., Piha-Paul, S., Ott, P.A., et al. (2019). Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecologic Oncology, 152(2), 243-250. doi:10.1016/J.YGYNO.2018.11.017
Wculek, S.K., Cueto, F.J., Mujal, A.M., Melero, I., Krummel, M.F., Sancho, D. (2020). Dendritic cells in cancer immunology and immunotherapy. Nature Reviews Immunology, 20(1), 7-24. doi:10.1038/S41577-019-0210-Z
Labidi-Galy, S.I., Sisirak, V., Meeus, P., et al. (2011). Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Research, 71(16), 5423-5434. doi:10.1158/0008-5472.CAN-11-0367
Labidi-Galy, S.I., Treilleux, I., Goddard-Leon, S., et al. (2012). Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. OncoImmunology, 1(3), 380-382. doi:10.4161/ONCI.18801
Harimoto, H., Shimizu, M., Nakagawa, Y., et al. (2013). Inactivation of tumor-specific CD8+CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunology and Cell Biology, 91(9), 545-555. doi:10.1038/ICB.2013.38
Munn, D.H. and Mellor, A.L. (2016). IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends in Immunology, 37(3), 193-207. doi:10.1016/J.IT.2016.01.002
Conrad, C., Gregorio, J., Wang, Y.H., et al. (2012). Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells. Cancer Research, 72(20), 5240-5249. doi:10.1158/0008-5472.CAN-12-2271
Lluesma, S.M., Wolfer, A., Harari, A., Kandalaft, L.E. (2016). Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines, 4(2). doi:10.3390/BIOMEDICINES4020010
Bol, K.F., Schreibelt, G., Gerritsen, W.R., de Vries, I.J.M., Figdor, C.G. (2016). Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res, 22(8), 1897-1906. doi:10.1158/1078-0432.ccr-15-1399
Zhang, X., He, T., Li, Y., et al. (2021). Dendritic Cell Vaccines in Ovarian Cancer. Frontiers in Immunology, 11, 613773. doi:10.3389/FIMMU.2020.613773/BIBTEX
Zhou, Y., Slone, N., Chrisikos, T.T., et al. (2020). Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 + conventional dendritic cells. Journal for ImmunoTherapy of Cancer, 8(1). doi:10.1136/JITC-2019-000474
Zhang, W., Lu, X., Cui, P., et al. (2019). Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunology, Immunotherapy, 68(1), 121-130. doi:10.1007/S00262-018-2257-2
Chu, C.S., Boyer, J., Schullery, D.S., et al. (2012). Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology, Immunotherapy, 61(5), 629-641. doi:10.1007/S00262-011-1081-8
Rahma, O.E., Ashtar, E., Czystowska, M., et al. (2012). A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy, 61(3), 373-384. doi:10.1007/S00262-011-1100-9
Schietinger, A., Philip, M., Schreiber, H. (2008). Specificity in cancer immunotherapy. Seminars in Immunology, 20(5), 276-285. doi:10.1016/j.smim.2008.07.001
Tang, L., Zhang, R., Zhang, X., Yang, L. (2021). Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications. Frontiers in Oncology, 11, 701777. doi:10.3389/FONC.2021.701777/BIBTEX
Hatfield, P., Merrick, A.E., West, E., et al. (2008). Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. Journal of Immunotherapy, 31(7), 620-32. doi: 10.1097/CJI.0b013e31818213df
Cho, D., Yang, W., Lee, H., et al. (2012). Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurgery, 77(5-6), 736-44. doi: 10.1016/j.wneu.2011.08.020
Di Nicola, M., Zappasodi, R., Carmelo, C.S., et al. (2009). Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood, 113(1), 18-27. doi:10.1182/blood-2008-06-165654
Palucka, A.K., Ueno, H., Connolly, J., et al. (2006). Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8 + T-cell immunity. J Immunother, 29(5), 545-557. doi:10.1097/01.cji.0000211309.90621.8b
Chiang, C.L.L., Kandalaft, L.E., Tanyi, J., et al. (2013). A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(17), 4801-4815. doi:10.1158/1078-0432.CCR-13-1185
Kobayashi, M., Chiba, A., Izawa, H., et al. (2014). The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of ovarian research, 7(1). doi:10.1186/1757-2215-7-48
Tanyi, J.L., Bobisse, S., Ophir, E., et al. (2018). Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science translational medicine, 10(436). doi:10.1126/SCITRANSLMED.AAO5931
Kandalaft, L.E., Powell, D.J., Chiang, C.L., et al. (2013). Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated t cells in recurrent ovarian cancer. OncoImmunology, 2(1). doi:10.4161/ONCI.22664
Lawrence, M.S., Stojanov, P., Polak, P., et al. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499(7457), 214-218. doi:10.1038/nature12213
O'Donnell, T., Christie, E.L., Ahuja, A., et al. (2018). Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer, 18(1), 87. doi:10.1186/s12885-017-3825-0
Ding, Z., Li, Q., Zhang, R., et al. (2021). Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduction and Targeted Therapy, 6(1). doi:10.1038/S41392-020-00448-5
Carreno, B.M., Magrini, V., Becker-Hapak, M., et al. (2015). A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science, 348(6236), 803-808. doi:10.1126/SCIENCE.AAA3828
Mullard, A. (2016). The cancer vaccine resurgence. Nature Reviews Drug Discovery, 15(10), 663-665. doi:10.1038/NRD.2016.201
Boisguérin, V., Castle, J.C., Loewer, M., et al. (2014). Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside. British Journal of Cancer, 111(8), 1469-1475. doi:10.1038/bjc.2013.820
Bassani-Sternberg, M., Gfeller, D. (2016). Unsupervised HLA peptidome deconvolution improves ligand prediction accuracy and predicts cooperative effects in peptide-HLA interactions. Journal of Immunology, 197(6), 2492-2499. doi:10.4049/jimmunol.1600808
Gfeller, D., Guillaume, P., Michaux, J., et al. (2018). The length distribution and multiple specificity of naturally presented HLA-I ligands. Journal of Immunology, 201(12), 3705-3716. doi:10.4049/jimmunol.1800914
Published
Issue
Section
License
Copyright (c) 2023 Jennifer Rowley (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
